Quince Therapeutics, Inc. (QNCX)

Market Cap	44.51M
Revenue (ttm)	n/a
Net Income (ttm)	-31.39M
Shares Out	43.22M
EPS (ttm)	-0.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,051
Open	1.030
Previous Close	1.060
Day's Range	1.030 - 1.085
52-Week Range	0.840 - 1.740
Beta	1.25
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2024

About QNCX

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patien...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 9, 2019
• Employees: 32
• Stock Exchange: NASDAQ
• Ticker Symbol: QNCX